RxDoctor Payments Data

Amanda Metzger, MD

Obstetrics & Gynecology · Quincy, MANPI 1699742643

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $13,183 of the $14,120 with a category attached, or 93.4%. Organon accounts for 80.4% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $8,046 and has fallen 94.9% since, to $410 in 2025. Among obstetrics & gynecology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,120in general payments, 2019–2025

Across 46 payments — averaging $306.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organon$11K
  • Merck$2K
  • AbbVie$249
  • Exeltis, USA Inc.$158
  • Astellas Pharma US Inc$96
  • Hologic Sales And Service, LLC$45
  • plus $96 from 3 others

What the payments were for

  • Speaking & faculty fees$13,18393%
  • Travel & lodging$2702%
  • Food & beverage$6675%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,120 in reported general payments places this provider in the 95th percentile of 910 obstetrics & gynecology providers in Massachusetts.

See all obstetrics & gynecology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$26,805
Medicare patients
209
Services billed
396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
YuvafemEstradiol37$6,706
Estradiol63$5,746
Clobetasol Propionate31$1,280
Raloxifene Hcl13$941
ValacyclovirValacyclovir Hcl15$633
Nystatin17$147

Paid to pharmacies, not to this prescriber.

Other obstetrics & gynecology in Quincy

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →